Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative cell therapies for cancer and other life-threatening diseases. Founded in 2004, Bellicum has made significant strides in the field of immunotherapy, particularly with its proprietary GoCAR-T™ technology, which enhances the efficacy and safety of CAR T-cell therapies. With a strong presence in the oncology sector, Bellicum is dedicated to advancing its core products, including BPX-601 and BPX-701, which are designed to target specific cancer antigens. The company has garnered attention for its unique approach to cell therapy, positioning itself as a leader in the rapidly evolving landscape of cancer treatment. Bellicum's commitment to innovation and patient-centric solutions underscores its notable achievements in the biopharmaceutical industry.
DitchCarbon Score
How does Bellicum Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bellicum Pharmaceuticals, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bellicum Pharmaceuticals, Inc.'s reported carbon emissions
Bellicum Pharmaceuticals, Inc., headquartered in the US, currently does not have available data on carbon emissions, as no specific emissions figures have been reported. Consequently, there are no defined reduction targets or climate commitments outlined by the company at this time. In the absence of concrete emissions data, it is essential to note that many companies in the biopharmaceutical sector are increasingly focusing on sustainability and climate action, often setting ambitious goals to reduce their carbon footprint. However, without specific commitments or targets from Bellicum Pharmaceuticals, it is unclear how they align with industry standards in addressing climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bellicum Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
